Table 2.

Comparison of HRU per Patient per Month Between Ibrutinib and CIT and Between Ibrutinib and BR During the Front-line Therapy Period^{b, c}

	RRd	95% CIe	P Valuee
Ibrutinib versus CIT
Monthly all-cause HRU
Number of inpatient admissions	0.74	0.48-1.17	.2400
Number of days of inpatient stay	0.92	0.49-1.83	.8200
Days with outpatient services	0.75	0.60-0.94	.0200a
Days with antineoplastic/CIT drug administration	0.05	0.01-0.13	<.0001a
Days with outpatient services related to the antineoplastic/CIT drug administration	0.09	0.03-0.19	<.0001a
Days with other outpatient services	1.01	0.80-1.28	.8240
Days with ER visits	0.89	0.57-1.46	.5360
Days with other services	0.77	0.49-1.31	.2520
Monthly cancer-related HRUf
Number of inpatient admissions	0.77	0.49-1.22	.3080
Number of days of inpatient stay	0.93	0.48-1.86	.8640
Days with outpatient services	0.64	0.51-0.82	.0080a
Days with antineoplastic/CIT drug administration	0.05	0.02-0.13	<.0001a
Days with outpatient services related to the antineoplastic/CIT drug administration	0.09	0.03-0.19	<.0001a
Days with other outpatient services	0.98	0.79-1.30	.8400
Days with ER visits	0.78	0.44-1.29	.2880
Days with other services	0.70	0.42-1.23	.1720
Ibrutinib versus BR
Monthly all-cause HRU
Number of inpatient admissions	0.87	0.55-1.34	.5000
Number of days of inpatient stay	1.32	0.70-2.37	.3960
Days with outpatient services	0.74	0.57-0.91	.0040a
Days with antineoplastic/CIT drug administration	0.04	0.01-0.09	<.0001a
Days with outpatient services related to the antineoplastic/CIT drug administration	0.07	0.02-0.16	<.0001a
Days with other outpatient services	1.01	0.78-1.25	.9200
Days with ER visits	1.01	0.56-1.74	.8680
Days with other services	0.94	0.49-1.61	.7600
Monthly cancer-related HRUf
Number of inpatient admissions	0.91	0.56-1.44	.7080
Number of days of inpatient stay	1.36	0.72-2.45	.3440
Days with outpatient services	0.65	0.51-0.79	<.0001a
Days with antineoplastic/CIT drug administration	0.04	0.01-0.09	<.0001a
Days with outpatient services related to the antineoplastic/CIT drug administration	0.07	0.02-0.16	<.0001a
Days with other outpatient services	1.04	0.82-1.30	.6600
Days with ER visits	0.91	0.42-1.97	.6800
Days with other services	0.88	0.44-1.56	.6520

Abbreviations: BR = Bendamustine/rituximab; CI = confidence interval; CIT = chemoimmunotherapy; ER = emergency room; HRU = health care resource utilization; RR = rate ratio.

^aIndicates P-value < .05.

^bHRU for the weighted populations were obtained by using inverse probability of treatment weights. The inverse probability of treatment weights were estimated based on propensity score. Variables used in the propensity score calculation included the following baseline characteristics: age, gender, region, quarter and year of index date, insurance plan type, time from first chronic lymphocytic lymphoma diagnosis to index date, Charlson comorbidity index, comorbidities (hypertension, lymphoma, deficiency anemias, diabetes, coagulation deficiency, chronic pulmonary disease), and baseline use of corticosteroids.

^cThe front-line therapy period was defined as the period from the initiation of the front-line therapy to the earliest among discontinuation of the front-line therapy (defined as a gap of more than 90 days between the last day of supply of a claim and the first day of supply of the next claim for the front-line therapy), initiation of a second-line therapy (a new antineoplastic agent not part of the front-line therapy), or end of data.

^dRRs were calculated using generalized linear models with Poisson distribution. Models were adjusted for baseline total all-cause costs.

^eCIs and P-values were obtained from non-parametric bootstrap procedures using 500 replicates.

^fCancer-related HRU was defined as claims with a primary or secondary diagnosis for cancer (International Classification of Diseases, Ninth Edition Clinical Modification codes: 140-239; International Classification of Diseases, Tenth Edition Clinical Modification codes: C00-D49).